Next-generation Graft Health Monitoring
Donor-derived cell-free DNA represents a new approach to an old problem in heart transplantation
-
By
-
Stephanie Anderson
-
May 4, 2026
-
Clinical Scorecard: Next-generation Graft Health Monitoring
At a Glance
| Category | Detail |
|---|
| Condition | Acute graft rejection post-heart transplantation |
| Key Mechanisms | Donor-derived cell-free DNA (dd-cfDNA) as a biomarker for allograft injury |
| Target Population | Patients recovering from heart transplantation |
| Care Setting | Post-transplant monitoring in clinical settings |
Key Highlights
- Acute graft rejection occurs in 30-45% of heart transplant patients.
- dd-cfDNA offers a non-invasive alternative to endomyocardial biopsy.
- High negative predictive value (97%) of dd-cfDNA makes it an ideal rule-out test.
- Standardization of dd-cfDNA cut-offs is needed across laboratories.
- Financial and structural barriers hinder the adoption of dd-cfDNA testing.
Guideline-Based Recommendations
Diagnosis
- Use dd-cfDNA as a non-invasive marker for acute graft rejection.
Management
- Transition from invasive biopsies to dd-cfDNA blood tests for monitoring.
Monitoring & Follow-up
- Monthly monitoring of dd-cfDNA levels in the first year post-transplant.
Risks
- Invasive procedures carry risks; dd-cfDNA testing reduces these.
Patient & Prescribing Data
Heart transplant recipients
dd-cfDNA testing could streamline post-transplant care and reduce patient burden.
Clinical Best Practices
- Implement high-quality cell-free DNA extraction methods.
- Utilize next-generation sequencing for accurate dd-cfDNA measurement.
- Establish a robust quality assurance framework for decentralized testing.
References
